These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 8585765

  • 1. Phosphatidyl-2',3'-dideoxy-3'-thiacytidine: synthesis and antiviral activity in hepatitis B-and HIV-1-infected cells.
    Xie H, Voronkov M, Liotta DC, Korba BA, Schinazi RF, Richman DD, Hostetler KY.
    Antiviral Res; 1995 Oct; 28(2):113-20. PubMed ID: 8585765
    [Abstract] [Full Text] [Related]

  • 2. Synthesis and biological evaluation of 2',3'-dideoxy-L-pyrimidine nucleosides as potential antiviral agents against human immunodeficiency virus (HIV) and hepatitis B virus (HBV).
    Lin TS, Luo MZ, Liu MC, Pai SB, Dutschman GE, Cheng YC.
    J Med Chem; 1994 Mar 18; 37(6):798-803. PubMed ID: 8145230
    [Abstract] [Full Text] [Related]

  • 3. Influence of stereochemistry on antiviral activities and resistance profiles of dideoxycytidine nucleosides.
    Van Draanen NA, Tisdale M, Parry NR, Jansen R, Dornsife RE, Tuttle JV, Averett DR, Koszalka GW.
    Antimicrob Agents Chemother; 1994 Apr 18; 38(4):868-71. PubMed ID: 7518218
    [Abstract] [Full Text] [Related]

  • 4. Anti-HIV and anti-HBV activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109.
    Balzarini J, Wedgwood O, Kruining J, Pelemans H, Heijtink R, De Clercq E, McGuigan C.
    Biochem Biophys Res Commun; 1996 Aug 14; 225(2):363-9. PubMed ID: 8753770
    [Abstract] [Full Text] [Related]

  • 5. Perspectives on the molecular mechanism of inhibition and toxicity of nucleoside analogs that target HIV-1 reverse transcriptase.
    Anderson KS.
    Biochim Biophys Acta; 2002 Jul 18; 1587(2-3):296-9. PubMed ID: 12084471
    [Abstract] [Full Text] [Related]

  • 6. Antiviral activity of 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2',3'-dideoxy-beta-L-cytidine (beta-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro.
    Lin TS, Luo MZ, Liu MC, Pai SB, Dutschman GE, Cheng YC.
    Biochem Pharmacol; 1994 Jan 20; 47(2):171-4. PubMed ID: 8304960
    [Abstract] [Full Text] [Related]

  • 7. Antiviral activity of phosphatidyl-dideoxycytidine in hepatitis B-infected cells and enhanced hepatic uptake in mice.
    Hostetler KY, Korba BE, Sridhar CN, Gardner MF.
    Antiviral Res; 1994 May 20; 24(1):59-67. PubMed ID: 7944313
    [Abstract] [Full Text] [Related]

  • 8. Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.
    Gao Q, Gu Z, Hiscott J, Dionne G, Wainberg MA.
    Antimicrob Agents Chemother; 1993 Jan 20; 37(1):130-3. PubMed ID: 8381634
    [Abstract] [Full Text] [Related]

  • 9. Pure nucleoside enantiomers of beta-2',3'-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro.
    Schinazi RF, Gosselin G, Faraj A, Korba BE, Liotta DC, Chu CK, Mathé C, Imbach JL, Sommadossi JP.
    Antimicrob Agents Chemother; 1994 Sep 20; 38(9):2172-4. PubMed ID: 7811039
    [Abstract] [Full Text] [Related]

  • 10. Comparative evaluation of L-Fd4C and related nucleoside analogs as promising antiviral agents.
    Chen SH.
    Curr Med Chem; 2002 May 20; 9(9):899-912. PubMed ID: 11966452
    [Abstract] [Full Text] [Related]

  • 11. Synthesis and antiviral activity of new carbonylphosphonate 2',3'-dideoxy-3'-thiacytidine conjugates.
    Charvet AS, Turin F, Faury P, Hantz O, Camplo M, Mourier N, Berthillon P, Graciet JC, Chermann JC, Trépo C.
    Antiviral Res; 1994 Oct 20; 25(2):161-8. PubMed ID: 7847877
    [Abstract] [Full Text] [Related]

  • 12. Anti-hepatitis B virus activity and metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine.
    Zhu YL, Dutschman DE, Liu SH, Bridges EG, Cheng YC.
    Antimicrob Agents Chemother; 1998 Jul 20; 42(7):1805-10. PubMed ID: 9661025
    [Abstract] [Full Text] [Related]

  • 13. Antiviral activity of 5'-O-carbonate-2',3'-dideoxy-3'-thiacytidine prodrugs against hepatitis B virus in HepG2 2.2.15 cells.
    Gagey D, Ravetti S, Castro EF, Gualdesi MS, Briñon MC, Campos RH, Cavallaro LV.
    Int J Antimicrob Agents; 2010 Dec 20; 36(6):566-9. PubMed ID: 20947311
    [Abstract] [Full Text] [Related]

  • 14. Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA.
    Delaney WE, Miller TG, Isom HC.
    Antimicrob Agents Chemother; 1999 Aug 20; 43(8):2017-26. PubMed ID: 10428929
    [Abstract] [Full Text] [Related]

  • 15. 2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo.
    Zoulim F, Dannaoui E, Borel C, Hantz O, Lin TS, Liu SH, Trépo C, Cheng YC.
    Antimicrob Agents Chemother; 1996 Feb 20; 40(2):448-53. PubMed ID: 8834896
    [Abstract] [Full Text] [Related]

  • 16. Effect of beta-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Implications for predicting drug hepatotoxicity.
    Cui L, Schinazi RF, Gosselin G, Imbach JL, Chu CK, Rando RF, Revankar GR, Sommadossi JP.
    Biochem Pharmacol; 1996 Nov 22; 52(10):1577-84. PubMed ID: 8937473
    [Abstract] [Full Text] [Related]

  • 17. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus.
    Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WS.
    J Virol; 1997 Dec 22; 71(12):9392-9. PubMed ID: 9371599
    [Abstract] [Full Text] [Related]

  • 18. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (--)-2',3'-dideoxy-3'-thiacytidine.
    Kavlick MF, Shirasaka T, Kojima E, Pluda JM, Hui F, Yarchoan R, Mitsuya H.
    Antiviral Res; 1995 Oct 22; 28(2):133-46. PubMed ID: 8585767
    [Abstract] [Full Text] [Related]

  • 19. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides.
    Schinazi RF, Lloyd RM, Nguyen MH, Cannon DL, McMillan A, Ilksoy N, Chu CK, Liotta DC, Bazmi HZ, Mellors JW.
    Antimicrob Agents Chemother; 1993 Apr 22; 37(4):875-81. PubMed ID: 7684216
    [Abstract] [Full Text] [Related]

  • 20. Anti-human immunodeficiency virus activities of the beta-L enantiomer of 2',3'-dideoxycytidine and its 5-fluoro derivative in vitro.
    Gosselin G, Schinazi RF, Sommadossi JP, Mathé C, Bergogne MC, Aubertin AM, Kirn A, Imbach JL.
    Antimicrob Agents Chemother; 1994 Jun 22; 38(6):1292-7. PubMed ID: 8092827
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.